DOCSLIB.ORG

Sr. Manager, Supply Chain | Save Apply Now ( Cytiva Burnaby, British Columbia, Canada Supply Chain & Logistics R1172287

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sr. Manager, Supply Chain | Save Apply Now ( Cytiva Burnaby, British Columbia, Canada Supply Chain & Logistics R1172287 Our Businesses % Our Purpose Our Difference Careers Blog Students % Search Jobs & Saved Jobs (0) Sr. Manager, Supply Chain | Save Apply Now ( Cytiva Burnaby, British Columbia, Canada Supply Chain & Logistics R1172287 1 C ) * Be​ part of something altogether life-changing! Get notified for similar jobs Working at Cytiva in the Life Sciences industry means being at the forefront of providing new solutions to transform Sign up to receive job alerts human health. Our incredible customers undertake life-saving activities ranging from fundamental biological research to developing innovative vaccines, new medicines, and cell and gene therapies. [email protected] Submit At Cytiva you will be able to continuously improve yourself and us – working on challenges that truly matter with people that care for each other, our customers, and their patients. With associates across 40 countries, Cytiva is a place where By clicking the "Submit" button you consent to every day is a learning opportunity – so you can grow your career and expand your skills in the long term. receive emails about similar jobs. You agree to the Cytiva is proud to work alongside a community of nine fellow Danaher Life Sciences companies. Together, we’re Terms of Use and acknowledge Danaher's Data pioneering the future of science and medicine, developing products that enable researchers in the fight to save lives. Privacy Policy. You may easily unsubscribe at any time. We are looking for a Leader for our growing Operations team in Burnaby! Develop and strengthen existing supply chain strategies, frameworks and tools that are integral to Vanrx’s growth. Lead, develop and support the overall direction for our Procurement, Sourcing, and Warehouse & Logistics departments. Get tailored job recommendations Develop and refine (current) KPIs, benchmarks, and other measures of success for Vanrx’s supply chain . based on your interests. Work with and support Sales Operations to ensure Vanrx continues to meet commercial schedules as planned. Use analytics to drive decisions, develop and execute sourcing strategies. Get Started Provide oversight of the materials warehouse, distribution, and storage to ensure accuracy. Be a stakeholder in product development discussions and ensure the supply chain is well represented. Support the identification and implementation of system initiatives to ensure continuous improvement projects and Share the opportunity efficiencies are gained. Apply Lean Manufacturing and Six Sigma tools to reduce waste and improve quality. 1 C ) * Provide thought leadership to support increased growth commercialization as it relates to supply chain and materials management activities. Identify, manage and lead continuous improvement projects to achieve or exceed operational metrics. Act as a key stakeholder in key initiatives across the company, advising on prioritization and design outcomes. Define and establish clear objectives and expectations, routinely provide direct feedback for performance management and development. Lead, motivate and mentor direct reports in achieving their respective goals. Identify projects and recommend appropriate courses of action (e.g., discontinuation, outsource, process improvement) to maximize profitability and supply. Who You Are Undergraduate degree in business, engineering, or a related discipline; MBA valued and would be an asset. 10+ years of progressive experience within a technical manufacturing environment. Experience in a leadership role within Operations or Supply Chain. History of managing a complex global supply base, including Asian and European supply markets. Strong knowledge and experience of international trade logistics, including requirements of commercial trade documents. Understanding of ERP Systems and Engineering Change implementation processes, including data management is an asset. Experience with lean manufacturing and process improvements. Exceptional leadership, interpersonal and communication skills. Excellent project management skills. Exceptional negotiation skills and proven ability to draft strategic agreements. #LI-AS7 When you join us, you’ll also be joining Danaher’s global organization, where 69,000 people wake up every day determined to help our customers win. As an associate, you’ll try new things, work hard, and advance your skills with guidance from dedicated leaders, all with the support of powerful Danaher Business System tools and the stability of a tested organization. At Danaher, we value diversity and the existence of similarities and differences, both visible and not, found in our workforce, workplace and throughout the markets we serve. Our associates, customers and shareholders contribute unique and different perspectives as a result of these diverse attributes. If you’ve ever wondered what’s within you, there’s no better time to find out. Apply Now ( | Save Personal Information Cookie Settings Danaher Careers Students Life Sciences Diagnostics Our Purpose Start Your Career at Danaher Life Sciences Overview Diagnostics Overview Our Difference Leadership Development Programs Beckman Coulter Life Sciences Beckman Coulter Diagnostics Locations Rotational Leadership Programs Cytiva Cepheid Danaher Corporate Summer Internship Program IDBS HemoCue Danaher Digital Connect With Us Integrated DNA Technologies (IDT) Leica Biosystems Diversity + Inclusion Leica Microsystems Mammotome Careers Blog Molecular Devices Radiometer Talent Community Pall Phenomenex SCIEX Water Quality Product Identification Water Quality Overview Product Identification Overview ChemTreat Alltec/FOBA Hach Esko McCrometer Videojet OTT HydroMet Laetus Trojan Technologies LINX X-Rite and Pantone C 1 # $ ©2020 Danaher. All Rights Reserved Accommodations and EEO Policy Statement | Privacy Policy | Fraudulent Offer Notice.
Load more

Recommended publications
  • Participant List
    Participant list Please find below a list of current participants in theAustralian Life Sciences Remuneration Review. For a complete list by super sector, sector and segment refer to Mercer WIN®. A. Menarini Australia B Braun Avitum Australia Cardinal Health AbbVie Australia Bausch & Lomb (Australia) Cepheid Abbott Australasia Baxter Healthcare Cochlear Acrux Bayer Coloplast Australia Alcon Beckman Coulter - Diagnostics Convatec (Australia) Alere Beckman Coulter - Life Sciences CooperVision Australia Allergan Becton Dickinson DH Dental Alphapharm Besins Healthcare Australia DSM Nutritional Products Amgen Biogen Idec Australia Device Technologies Aust Ascom Australia Biomerieux Australia Ecolab Aspen Australia Blackmores Edwards Lifesciences Astellas Pharma Boehringer Ingelheim Eisai Australia AstraZeneca Boston Scientific International Elanco Australasia Australian Nuclear Science and Technology Boucher & Muir Eli Lilly Australia Organisation (ANSTO) Bristol-Myers Squibb Evolution Health Australian Pharmaceutical Industries CSL Ferring Pharmaceuticals B Braun Australia © September 2020 Mercer Consulting (Australia) Pty Ltd Australian Life Sciences Remuneration Review 4.1 Participant list Fresenius Kabi Australia Integrated DNA Technologies (IDT) Merck Serono Fresenius Medical Care Australia Invisalign Australia Mindray Medical International GE Australia Healthcare Ipsen Molnlycke Health Care GN Netcom Australia J&J Pacific Mundipharma Galderma Australia Janssen-Cilag - Australia Nevro Medical Australia Getinge Johnson & Johnson Medical
    [Show full text]
  • 2019 Annual Report
    1984 2019 2019 MARKED DANAHER’S 35TH ANNIVERSARY To honor this milestone, the front cover of this year's annual report features the original Danaher logo and bright blue color palette. We proudly celebrate our company's history as the prelude to a 35 future filled with opportunity. By living our core values of building the best team, continuously improving, “ listening to our customers every day and driving innovation, we ultimately deliver long-term shareholder value.” Thomas P. Joyce, Jr. Financial Operating Highlights (dollars in millions except per share data and number of associates) 2019 2018 Sales $ 17,911.1 $ 17,048.5 Operating Profit $ 3,269.4 $ 3,055.1 Net Earnings $ 2,432.3 $ 2,406.3 Net Earnings Per Share (diluted) $ 3.26 $ 3.39 Operating Cash Flow $ 3,657.4 $ 3,644.0 Investing Cash Flow $ (1,166.1) $ (2,873.9) Financing Cash Flow $ 16,589.9 $ (797.4) Capital Expenditures $ (635.5) $ (583.5) Capital Disposals $ 12.8 $ 6.3 Free Cash Flow (Operating Cash Flow less Capital Expenditures plus Capital Disposals) $ 3,034.7 $ 3,066.8 Number of Associates 60,000 58,000 Total Assets* $ 62,081.6 $ 47,832.5 Total Debt ** $ 21,729.1 $ 9,740.3 Stockholders’ Equity $ 30,281.9 $ 28,226.7 Total Capitalization (Total Debt plus Stockholders’ Equity) $ 52,011.0 $ 37,967.0 * 2018 data includes both continuing and discontinued operations ** Long-Term Debt ($21,516.7 for 2019 and $9,688.5 for 2018) plus Notes Payable and Current Portion of Long-Term Debt ($212.4 for 2019 and $51.8 for 2018) All financial data set forth in this annual report relates solely to continuing operations unless otherwise indicated.
    [Show full text]
  • Eprocurement Small Order Process: Vendors with Item Catalogs
    eProcurement Small Order Process: Vendors with Item Catalogs Updated April 18, 2012 V000142495 ABCAM INC V000137051 ILLUMINA INC V000081265 ACO MEDICAL SUPPLY V000014509 INTERMOUNTAIN SCIENTIFIC V000125369 ACTIVE MOTIF V000080847 INTREX COMPUTERS INC V000112094 AFFYMETRIX INC V000006118 INVITROGEN CORPORATION V000114793 AGILENT TECHNOLOGIES INC V000130596 INVIVOGEN V000000082 ALLTECH ASSOCIATES INC V000005714 JACKSON IMMUNORES V000000118 AMRESCO V000001442 JACKSON LAB V000152997 ANASPEC INC V000001558 LABORATORY SAFETY V000132756 ASYLUM RESEARCH CORP V000047258 LABREPCO INC V000000126 ATCC V000108167 LEICA MICROSYSTEMS V000068824 ATLANTA BIOLOGICALS V000088788 LI-COR INC V000162435 ATLANTIC FITNESS V000111733 LIST BIOLOGICAL LABS V000000307 BASI V000002832 LONZA WALKERSVILLE INC V000000261 BD BIOSCIENCES V000149811 MATRIX TECH V000000259 BECKMAN COULTER V000135360 MEDICAL SPECIALTIES V000176191 BENCHMARK TECH V000022962 MIDWEST SCIENTIFIC V000101618 BETHYL LABS V000078901 MILTENYI BIOTEC INC V000159330 BIO BASIC V000008542 MOLECULAR DEVICES INC V000004901 BIOGENIX LABORATORIES V000001340 MP BIOMEDICALS V000145647 BIOLEGEND V000188293 NETA SCIENTIFIC INC V000157241 BIOLINE USA INC V000186184 NEWEAST BIOSCIENCES V000112934 BIOLOGICAL SPECIALTY CORP V000001880 NEW ENGLAND BIOLABS INC V000000303 BIO-RAD V000004850 NEWPORT V000000305 BIO-TEK INSTRUMENTS V000052248 NIKON INSTRUMENTS INC V000000349 BRAINTREE V000167597 OCEAN OPTICS V000190375 BUTLER SCHEIN V000001937 OLYMPUS AMERICA INC V000000429 CAMCOR V000139707 OPEN BIOSYSTEMS V000000454
    [Show full text]
  • 2017 INVESTOR & ANALYST DAY December 14, 2017
    2017 INVESTOR & ANALYST DAY December 14, 2017 Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, deterioration of or instability in the economy, the markets we serve and the financial markets, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including regulations relating to medical devices and the health care industry), our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify, consummate and integrate appropriate acquisitions and successfully complete divestitures and other dispositions, our ability to integrate the recent acquisitions of Pall Corporation and Cepheid and achieve the anticipated benefits of such transactions, contingent
    [Show full text]
  • 2010 Annual Report
    2010 ANNUAL REPORT Segmentation Voice of the Customer Dynamic Resource Allocation Brand Management Policy Deployment MEASURING Risk Management Value Selling Innovation Talent SUCCESS Accelerated Product Development Sales Force Initiatives Emerging Markets Digital Marketing DBS 2010 ANNUAL REPORT In 2010, Danaher updated reporting segments to reflect the evolution of our business to a science and technology company. We now report results in five business segments: Test & Measurement; Environmental; Life Sciences & Diagnostics; Dental; and Industrial Technologies. TEST & MEASUREMENT Our Test & Measurement segment is a leading, global provider of electronic measurement instruments and monitoring, management and optimization tools for communications and enterprise networks and related services. Our products are used in the design, development, manufacture, installation, deployment and operation of electronics equipment and communications networks and services. Customers for our products and services include manufacturers of electronic instruments; service, installation and maintenance professionals; network equipment manufacturers who design, develop, manufacture and install network equipment and service providers who implement, maintain and manage communications networks and services. Also included in our Test & Measurement segment are our mobile tool and wheel service businesses. Financial Operating Highlights 2010 2009 (dollars in thousands except per share data and number of associates) Sales $ 13,202,602 $ 11,184,938 Operating profit
    [Show full text]
  • Case No COMP/M.6175 - DANAHER/ BECKMAN COULTER
    EN Case No COMP/M.6175 - DANAHER/ BECKMAN COULTER Only the English text is available and authentic. REGULATION (EC) No 139/2004 MERGER PROCEDURE Article 6(1)(b) NON-OPPOSITION Date: 16/06/2011 In electronic form on the EUR-Lex website under document number 32011M6175 Office for Publications of the European Union L-2985 Luxembourg EUROPEAN COMMISSION Brussels, 16.06.2011 C(2011)4423 In the published version of this decision, some information has been omitted pursuant to Article PUBLIC VERSION 17(2) of Council Regulation (EC) No 139/2004 concerning non-disclosure of business secrets and other confidential information. The omissions are MERGER PROCEDURE shown thus […]. Where possible the information omitted has been replaced by ranges of figures or a ARTICLE 6(1)(b) DECISION general description. To the notifying party: Dear Sir/Madam, Subject: Case No COMP/M.6175 - Danaher/ Beckman Coulter Commission decision pursuant to Article 6(1)(b) of Council Regulation No 139/20041 1. On 6 May 2011, the European Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 by which the undertaking Djanet Acquisition Corp. (USA) controlled by Danaher Corporation (USA) ("Danaher") acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of the undertaking Beckman Coulter, Inc. (USA) ("Beckman") by way of public bid announced on 15 February 2011. Danaher and Beckman are designated hereinafter as the "parties (to the proposed transaction)"2. 1 OJ L 24, 29.1.2004, p. 1 ("the Merger Regulation").
    [Show full text]
  • 2018 Annual Report
    2018 Annual Report Danaher 2018 Annual Report Financial Operating Highlights (dollars in millions except per share data and number of associates) 2018 2017 Sales $ 19,893.0 $ 18,329.7 Operating Profit $ 3,403.8 $ 2,990.4 Net Earnings $ 2,650.9 $ 2,469.8 Net Earnings Per Share (diluted) $ 3.74 $ 3.50 Operating Cash Flow $ 4,022.0 $ 3,477.8 Investing Cash Flow $ (2,949.4) $ (843.4) Financing Cash Flow $ (797.4) $ (3,098.5) Capital Expenditures $ (655.7) $ (619.6) Capital Disposals $ 6.3 $ 32.6 Free Cash Flow (Operating Cash Flow less Capital Expenditures plus Capital Disposals) $ 3,372.6 $ 2,890.8 Number of Associates 71,000 67,000 Total Assets $ 47,832.5 $ 46,648.6 Total Debt * $ 9,740.3 $ 10,522.1 Stockholders’ Equity $ 28,226.7 $ 26,367.8 Total Capitalization (Total Debt plus Stockholders’ Equity) $ 37,967.0 $ 36,889.9 * Long-Term Debt ($9,688.5 for 2018 and $10,327.4 for 2017) plus Notes Payable and Current Portion of Long-Term Debt ($51.8 for 2018 and $194.7 for 2017) All financial data set forth in this annual report relates solely to continuing operations unless otherwise indicated. 2018 Annual Report Dear Shareholders, As I begin my 30th year at Danaher, it is humbling to reflect on what our team has achieved over that time and exciting to think about the opportunities that still lie ahead. Financially and strategically, 2018 was an outstanding year. With the Danaher Business System (DBS) as our driving force, we strengthened our footholds in attractive, fast-growing markets and enhanced our competitive positions.
    [Show full text]
  • Beckman Coulter Expanding Operations
    NEWS RELEASE Contacts: Hillary Hunter, Public Relations Phone: (561) 714-7826 E-mail: [email protected] Steve Ernst, Veris Communications Phone: (973) 702-7249 E-mail: [email protected] FOR IMMEDIATE RELEASE Beckman Coulter Life Sciences Expands Particle Characterization Group, Adds Hach Company’s Particle Counting Division Combined Businesses to Offer World-Class Expertise, Service and Solutions INDIANAPOLIS – October 21, 2013 – Beckman Coulter Life Sciences announces it is combining its Particle Characterization business with the Particle Counting business from Hach Company. This move brings together Beckman Coulter’s expertise in cell viability, particle sizing and particle analysis with Hach’s prominence in air and liquid particle counting, and will enable deeper particle characterization solutions, world-class customer support and superior service. In some countries the transition is subject to completing consultation and/or information with certain employee representative bodies. “This is an exciting time in the histories of these two storied enterprises,” said Jennifer Honeycutt, president, Beckman Coulter Life Sciences. “The Coulter, MET ONE and HIAC™ brands helped found the particle counting and characterization industry. Bringing them together allows us to continue to build on the success of these businesses and bring tremendous value to our customers.” Personnel from the particle counting business of Hach will transition into the Beckman Coulter Life Sciences business to work alongside the Particle Characterization team. Combing these two leading, Danaher Corporation-owned life science companies redefines the Beckman Coulter Particle Characterization business and uniquely positions it to provide innovative technologies to a number of important markets. For more information, please visit www.particle.com.
    [Show full text]
  • Appendices Due to Concerns Over the Quality of the Data Collected
    APPENDIX A WSU 2014-19 STRATEGIC PLAN Appendix A: WSU Strategic Plan 2014-15 Strategic Plan 2014-2019 President Elson S. Floyd, Ph.D. Strategic Plan 2014-2019 Introduction The 2014-19 strategic plan builds on the previous five-year plan, recognizing the core values and broad mission of Washington State University. Goals and strategies were developed to achieve significant progress toward WSU’s aspiration of becoming one of the nation’s leading land-grant universities, preeminent in research and discovery, teaching, and engagement. The plan emphasizes the institution’s unique role as an accessible, approachable research institution that provides opportunities to an especially broad array of students while serving Washington state’s broad portfolio of social and economic needs. While providing exceptional leadership in traditional land-grant disciplines, Washington State University adds value as an integrative partner for problem solving due to its innovative focus on applications and its breadth of program excellence. The plan explicitly recognizes the dramatic changes in public funding that have occurred over the duration of the previous strategic plan, along with the need for greater institutional nimbleness, openness, and entrepreneurial activity that diversifies the University’s funding portfolio. In addition, the plan reaffirms WSU’s land-grant mission by focusing greater attention system-wide on increasing access to educational opportunity, responding to the needs of Washington state through research, instruction, and outreach, and contributing to economic development and public policy. While the new plan retains the four key themes of the previous plan, its two central foci include offering a truly transformative educational experience to undergraduate and graduate students and accelerating the development of a preeminent research portfolio.
    [Show full text]
  • Envista Holdings Corp NVST
    14 October 2019 Equity Research Americas | United States Envista Holdings Corp NVST Bracing for Growth; Initiate Neutral; $30 Target Price Target price (12M, US$) 30.00 [V] Life Science Tools and Diagnostics | Initiation Neutral ■ Initiate Neutral; $30 Target Price: As a leading global manufacturer of dental, NVST is Price (11 Oct 19, US$) 27.93 levered to a seemingly stabilizing underlying dental industry backdrop, where it supports 52-week price range 29.07 - 26.59 90% of practitioners’ clinical needs. We expect earnings growth to accelerate on dedicated Market cap (US$ m) 4,431.13 innovation efforts, greater penetration in high-growth markets, and efficiency initiatives as a Enterprise value (US$ m) 5,650.91 [V] = Stock Considered Volatile (see Disclosure Appendix) more nimble standalone entity, as the recent spinoff of Danaher’s Dental segment. All in, these drivers should accelerate organic revenue growth to +low to mid-single digits over the next five years, with earnings growing at a +7% CAGR from 2019E-2023E. Research Analysts ■ Positioning for Growth via Targeted Innovation: While dental demand trends have Erin Wilson Wright been lackluster over the past few years, we view rising dental utilization stemming from 212 538 4080 favorable demographics, an emphasis on aesthetic and preventative care, along with [email protected] expanding adoption of digital dentistry should drive improving demand for dental Katie Tryhane consumables and equipment long term. For NVST, reinvigorated innovation, focused on 212 325 2713 Specialty products (i.e. N1 Implants, Spark Clear Aligners), an inherently faster growing [email protected] category (48% of sales), should spur growth, alongside efforts to fortify Dental Support Org.
    [Show full text]
  • 2012 Annual Report 1 Table of Contents
    2012 ANNUAL REPORT 1 TABLE of CONTENTS Environmental 2 Test & Measurement 4 Dental 6 Life Sciences & Diagnostics 8 Industrial Technologies 10 Letter to the Shareholders 12 2012 Form 10-K 16 Supplemental Financial Information 141 Directors & Executive Officers 143 Shareholder Information 144 DANAHER FINANCIAL OPERATING HIGHLIGHTS (dollars in millions, except per share data and number of associates) 2012 2011 Sales* $ 18,260.4 $ 16,090.5 Operating Profit* $ 3,165.1 $ 2,617.2 Net Earnings* $ 2,299.3 $ 1,935.3 Earnings per share (diluted)* $ 3.23 $ 2.77 Operating Cash Flow* $ 3,502.1 $ 2,732.1 Capital Expenditures* $ 458.3 $ 334.5 Free Cash Flow (operating cash flow less capital expenditures)* $ 3,043.8 $ 2,397.6 Number of Associates 63,000 59,000 Total Assets $ 32,941.0 $ 29,949.5 Total Debt $ 5,343.1 $ 5,305.2 Stockholders’ Equity $ 19,083.9 $ 16,971.8 Total Capitalization (total debt plus stockholders’ equity) $ 24,427.0 $ 22,277.0 *from continuing operations Environmental We provide products that help protect our water supply and air quality by serving two primary markets: water quality and retail/commercial petroleum. Our water quality business provides instrumentation and disinfection systems to help analyze and manage the quality of ultra- pure, potable, waste, ground and ocean water in residential, commercial, industrial and natural resource applications. Our retail/commercial petroleum business is a leading worldwide provider of solutions and services focused on fuel dispensing, remote fuel management, point-of- sale systems, payment systems and environmental compliance. 3 Test & Measurement We are a global provider of electronic measurement instruments, professional test tools, thermal imaging and calibration equipment used in electrical and industrial applications.
    [Show full text]
  • Company Vendor ID (Decimal Format) (AVL) Ditest Fahrzeugdiagnose Gmbh 4621 @Pos.Com 3765 0XF8 Limited 10737 1MORE INC
    Vendor ID Company (Decimal Format) (AVL) DiTEST Fahrzeugdiagnose GmbH 4621 @pos.com 3765 0XF8 Limited 10737 1MORE INC. 12048 360fly, Inc. 11161 3C TEK CORP. 9397 3D Imaging & Simulations Corp. (3DISC) 11190 3D Systems Corporation 10632 3DRUDDER 11770 3eYamaichi Electronics Co., Ltd. 8709 3M Cogent, Inc. 7717 3M Scott 8463 3T B.V. 11721 4iiii Innovations Inc. 10009 4Links Limited 10728 4MOD Technology 10244 64seconds, Inc. 12215 77 Elektronika Kft. 11175 89 North, Inc. 12070 Shenzhen 8Bitdo Tech Co., Ltd. 11720 90meter Solutions, Inc. 12086 A‐FOUR TECH CO., LTD. 2522 A‐One Co., Ltd. 10116 A‐Tec Subsystem, Inc. 2164 A‐VEKT K.K. 11459 A. Eberle GmbH & Co. KG 6910 a.tron3d GmbH 9965 A&T Corporation 11849 Aaronia AG 12146 abatec group AG 10371 ABB India Limited 11250 ABILITY ENTERPRISE CO., LTD. 5145 Abionic SA 12412 AbleNet Inc. 8262 Ableton AG 10626 ABOV Semiconductor Co., Ltd. 6697 Absolute USA 10972 AcBel Polytech Inc. 12335 Access Network Technology Limited 10568 ACCUCOMM, INC. 10219 Accumetrics Associates, Inc. 10392 Accusys, Inc. 5055 Ace Karaoke Corp. 8799 ACELLA 8758 Acer, Inc. 1282 Aces Electronics Co., Ltd. 7347 Aclima Inc. 10273 ACON, Advanced‐Connectek, Inc. 1314 Acoustic Arc Technology Holding Limited 12353 ACR Braendli & Voegeli AG 11152 Acromag Inc. 9855 Acroname Inc. 9471 Action Industries (M) SDN BHD 11715 Action Star Technology Co., Ltd. 2101 Actions Microelectronics Co., Ltd. 7649 Actions Semiconductor Co., Ltd. 4310 Active Mind Technology 10505 Qorvo, Inc 11744 Activision 5168 Acute Technology Inc. 10876 Adam Tech 5437 Adapt‐IP Company 10990 Adaptertek Technology Co., Ltd. 11329 ADATA Technology Co., Ltd.
    [Show full text]